EGFR and neoplasm: Moreover, blockade of EGFR/ERK/NFκB and EGFR/PI3K/NFκB signaling not only decreases IL6 and IL6R-associated chemoresistance in OC but also, when combined with an anti-IL6 antibody (Tocilizumab), potentiates the anti-tumor effect [205].